SCYNEXIS - רווח למניה אחת ב-12 החודשים האחרונים SCYX

The price history of SCYNEXIS, Inc. (SCYX) shares on the GURU.Markets platform demonstrates EPS TTM dynamics, which currently stand at 72.20. Growth for SCYNEXIS, Inc. (SCYX) is driven by Brexafemme sales, partner payments, and new tests against hospital-acquired pathogens. Patent protection ensures pricing power, although profits remain dependent on insurance reimbursements. This enables the brand to build a resistance-fighting network by introducing unique antifungal agents into medicine.

When selecting assets with a high margin of safety, the dynamics of net earnings per share, which reflect real capital efficiency, are critically important. Analyzing the year-over-year change in EPS (TTM) allows for an assessment of the resilience of SCYNEXIS, Inc. (SCYX) to borrowing costs and market pressure, which is particularly significant during the implementation of costly antifungal developments in collaboration with GSK and other global partners.